Plasma and tissue disposition of danofloxacin in brown trout (Salmo trutta fario) after intravenous and intramuscular administrations

ABSTRACT

Plasma and muscle pharmacokinetics of danofloxacin were investigated after 10 mg/kg intravenous (IV, caudal vein) and intramuscular (IM, right epaxial muscles) administrations in 168 healthy brown trout (Salmo trutta fario) at 10°C–13°C. High-performance liquid chromatography was used to determine its plasma and muscle concentrations. Pharmacokinetic parameters were analysed with a non-compartmental model. After IV administration, elimination half-life (t_1/2ʎz), area under the concentration–time curve (AUC_0–∞), mean residence time (MRT_0–∞), volume of distribution at steady state, total body clearance in plasma and AUC_Muscle/AUC_Plasma ratio were 22.22 h, 140.66 h*µg/mL, 23.15 h, 2.28 L/kg, 0.07 L/h/kg and 3.79, respectively. After IM administration, t_1/2ʎz, AUC_0–∞, MRT_0–∞, peak concentration (C_max), time to reach C_max, bioavailability in plasma and AUC_Muscle/AUC_Plasma ratio were 28.28 h, 84.39 h*µg/mL, 37.31 h, 4.79 µg/mL, 1 h, 59.99% and 8.46, respectively. Danofloxacin exhibited long t_1/2ʎz and good bioavailability after IM administration. Therefore, 10 mg/kg IM administration of danofloxacin in brown trout can provide AUC_0–24/MIC of > 125 and C_max/MIC of > 10 to treat diseases caused by susceptible bacteria with ≤ 0.336 µg/mL MIC.

KEYWORDS:

• Danofloxacin
• brown trout
• bioavailability
• tissue
• pharmacokinetics

Acknowledgments

This study will be presented in abstract form  to  the  International  Health  Sciences  Conference (IHSC) Diyarbakir, Turkey, 14-17 November 2018.

Disclosure statement

No potential conflict of interest was reported by the authors.